{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:02:15Z","timestamp":1787313735454,"version":"build-2736575974"},"reference-count":141,"publisher":"Informa UK Limited","issue":"13","funder":[{"name":"internal funds"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.2217\/fon.15.85","type":"journal-article","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T10:48:49Z","timestamp":1436525329000},"page":"1863-1880","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["Sorafenib: 10 years after the first pivotal trial"],"prefix":"10.1080","volume":"11","author":[{"given":"Gennaro","family":"Gadaleta-Caldarola","sequence":"first","affiliation":[{"name":"Medical Oncology Unit,\u2018Mons. R Dimiccoli\u2019 Hospital,\rViale Ippocrate, 15,\r76121 Barletta,\rAsl BAT,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Infusino","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit,\u2018S Francesco di Paola\u2019 Hospital,\rVia Promintesta,\r87027 Paola,\rASP,\rCosenza,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Divella","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology \u2013 National Cancer Institute \u2018Giovanni Paolo II\u2019,\rViale Orazio Flacco 65,\r70124,\rBari,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine & Clinical Specialties,University of Rome \u2018La Sapienza\u2019,\rPoliclinico Umberto I, Viale del Policlinico, 155,\r00161 Roma,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mazzocca","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine,University of Bari School of Medicine,\rPiazza G Cesare, 11,\r70124 Bari,\rItaly,\rNational Institute for Digestive Diseases,\rIRCCS \u2018Saverio De Bellis\u2019,\rVia Turi 27,\r70013,\rCastellana Grotte,\rBari,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"De Rose","sequence":"additional","affiliation":[{"name":"Psychoncology Unit,\rDSM Cosenza,\rASP,\rCosenza,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Filippelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit,\u2018S Francesco di Paola\u2019 Hospital,\rVia Promintesta,\r87027 Paola,\rASP,\rCosenza,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Abbate","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Pathology \u2013 National Cancer Institute \u2018Giovanni Paolo II\u2019,\rViale Orazio Flacco 65,\r70124,\rBari,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Brandi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit,\u2018Mons. R Dimiccoli\u2019 Hospital,\rViale Ippocrate, 15,\r76121 Barletta,\rAsl BAT,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,7,10]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2130"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986712799320736"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.124"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2658"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602584"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi310"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-4-426"},{"key":"e_1_3_2_11_1","unstructured":"Nevaxar Summary of Products Characteristics\n. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000690\/WC500027704.pdf."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(03)00056-9"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-12-1404"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(03)00027-2"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2530"},{"issue":"18","key":"e_1_3_2_16_1","first-page":"4182","article-title":"Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma","volume":"55","author":"Oka H","year":"1999","unstructured":"Oka H , ChataniY, HoshinoRet al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res.55(18), 4182\u20134187 (1999).","journal-title":"Cancer Res."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6723"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp411"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq651"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24864"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.48"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3961"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.3342"},{"issue":"4","key":"e_1_3_2_26_1","article-title":"SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)\/sunitinib (SU) versus SU\/SO in the treatment of metastatic renal cell cancer (mRCC)","volume":"32","author":"Michel MS","year":"2014","unstructured":"Michel MS , VervenneW, de SantisMet al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)\/sunitinib (SU) versus SU\/SO in the treatment of metastatic renal cell cancer (mRCC). J. Clin. Oncol.32(4), Abstract 393 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt375"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4940"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70030-0"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287212457216"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27632"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu259"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00648.x"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3441"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_3_2_37_1","volume-title":"2010 ASCO Gastrointestinal Cancers Symposium","author":"Chao Y","year":"2010","unstructured":"Chao Y , YoonJ, LiCet al. Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Presented at: 2010 ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22\u201324 January 2010."},{"key":"e_1_3_2_38_1","volume-title":"47th Annual Meeting of the American Society of Clinical Oncology","author":"Erhardt A","year":"2011","unstructured":"Erhardt A , KolligsFT, DollingerMMet al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: final results of the multicenter SOCRATES study. Presented at: 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 3\u20137 June 2011."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04697.x"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.006"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1021"},{"key":"e_1_3_2_42_1","volume-title":"2012 Gastrointestinal Cancers Symposium","author":"Lencioni R","year":"2012","unstructured":"Lencioni R , LlovetJM, HanGet al. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. Presented at: 2012 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 4\u20138 January 2012."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12622"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2376"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.4006"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12159"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24644"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.12.58"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02940.x"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12352"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.4126"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2014.920694"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/913634"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i3.786"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.016"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0143"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.00991.x"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2012.04.001"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000342425"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182468039"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.030"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0221"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.10"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.8372"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.3298"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4410"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.7746"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3009"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7189"},{"key":"e_1_3_2_70_1","unstructured":"A Multicenter Open-Label Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma. www.clinicaltrials.gov\/ct2\/show\/NCT01761266."},{"key":"e_1_3_2_71_1","volume-title":"SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations)","author":"Howlader N","year":"2011","unstructured":"Howlader N , NooneAM, KrapchoMet al. SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations). Bethesda, MD, USA: National Cancer Institute; 2011. http:\/\/seer.cancer.gov\/csr\/1975_2009_pops09."},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S49430"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.4.8388"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0987"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0921"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3279"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0702"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0405"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0068"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2717"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0129"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0103"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32832b2ea0"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5242"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0233"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010386226"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7771"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.689824"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.005"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3177"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.10.41"},{"key":"e_1_3_2_93_1","volume-title":"2011 European Multidisciplinary Cancer Congress (EMCC)","author":"Mariani C","year":"2011","unstructured":"Mariani C , BurdaevaO, RomaL. A double-blind, randomized Phase Iib study evaluating the efficacy and safety of sorafenib compared with placebo when administered in combination with docetaxel and\/or letrozole in patients with metastatic breast cancer: FM-B07-01 trial. Presented at: 2011 European Multidisciplinary Cancer Congress (EMCC). Stockholm, Sweden, 23\u201327 September 2011."},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2014.17.1.61"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-14-228"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.14.5691"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023393026"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.0541"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2011.554476"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.12.014"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25448"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1321"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7646"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8274.CD-10-0010"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1779"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1818"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826149ba"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014522491"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61857-1"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0484"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0190"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2667"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0553"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.10009"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.10.009"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9795-9"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17951-3"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.208"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4881"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8288"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7636"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.1529"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4495"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0237"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26334"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds607"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr151"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3322"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21637"},{"key":"e_1_3_2_130_1","unstructured":"National Comprehensive Cancer Network Distress management version 2.2013. NCCN.org."},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.8922"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000258732.80710.05"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09437.x"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0345-2"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.139"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.09.002"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.08.005"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.023"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.161"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-S2-23"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.01.002"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.07.004"},{"key":"e_1_3_2_143_1","first-page":"A2909","article-title":"Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma","volume":"47","author":"Elting J","year":"2006","unstructured":"Elting J , BigwoodD, Brown-ShimerSet al. Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. Proc. Am. Assoc. Cancer Res.47, A2909 (2006).","journal-title":"Proc. Am. Assoc. Cancer Res."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.85","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:45:24Z","timestamp":1719110724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":141,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.2217\/fon.15.85"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.85","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}